Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Work In Process: 2017-2024

Historic Work In Process for Adma Biologics (ADMA) over the last 6 years, with Dec 2024 value amounting to $61.6 million.

  • Adma Biologics' Work In Process fell 16.82% to $44.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.5 million, marking a year-over-year decrease of 16.82%. This contributed to the annual value of $61.6 million for FY2024, which is 24.22% up from last year.
  • Adma Biologics' Work In Process amounted to $61.6 million in FY2024, which was up 24.22% from $49.6 million recorded in FY2023.
  • Adma Biologics' 5-year Work In Process high stood at $61.6 million for FY2024, and its period low was $30.3 million during FY2020.
  • Moreover, its 3-year median value for Work In Process was $56.2 million (2022), whereas its average is $55.8 million.
  • Its Work In Process has fluctuated over the past 5 years, first surged by 94.66% in 2021, then declined by 11.66% in 2023.
  • Yearly analysis of 5 years shows Adma Biologics' Work In Process stood at $30.3 million in 2020, then soared by 94.66% to $59.0 million in 2021, then declined by 4.74% to $56.2 million in 2022, then declined by 11.66% to $49.6 million in 2023, then climbed by 24.22% to $61.6 million in 2024.